Overview

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.

Phase:

Phase 2

Details

Lead Sponsor:

University of Michigan Cancer Center
University of Michigan Rogel Cancer Center

Collaborators:

Dana-Farber Cancer Institute
Vanderbilt University Medical Center

Treatments:

Antibodies, Monoclonal
Nivolumab
Poly(ADP-ribose) Polymerase Inhibitors
Rucaparib